Barclays’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-197
| Closed | -$6 | – | 5584 |
|
|
2022
Q4 | $6 | Hold |
197
| – | – | ﹤0.01% | 5248 |
|
|
2022
Q3 | $0 | Hold |
197
| – | – | ﹤0.01% | 5311 |
|
|
2022
Q2 | $0 | Sell |
197
-31,698
| -99% | -$30.3K | ﹤0.01% | 5455 |
|
|
2022
Q1 | $43K | Buy |
31,895
+2,181
| +7% | +$3.54K | ﹤0.01% | 4179 |
|
|
2021
Q4 | $78K | Sell |
29,714
-2,909
| -9% | -$8.79K | ﹤0.01% | 3779 |
|
|
2021
Q3 | $101K | Sell |
32,623
-1,147
| -3% | -$3.83K | ﹤0.01% | 3900 |
|
|
2021
Q2 | $126K | Buy |
33,770
+21,016
| +165% | +$70K | ﹤0.01% | 3754 |
|
|
2021
Q1 | $45K | Buy |
12,754
+7,831
| +159% | +$31.8K | ﹤0.01% | 4225 |
|
|
2020
Q4 | $16K | Sell |
4,923
-5,427
| -52% | -$19.4K | ﹤0.01% | 4706 |
|
|
2020
Q3 | $36K | Sell |
10,350
-7,175
| -41% | -$28.9K | ﹤0.01% | 4746 |
|
|
2020
Q2 | $80K | Buy |
17,525
+6,890
| +65% | +$30.5K | ﹤0.01% | 4667 |
|
|
2020
Q1 | $35K | Sell |
10,635
-11,334
| -52% | -$51.9K | ﹤0.01% | 5420 |
|
|
2019
Q4 | $134K | Buy |
21,969
+6,403
| +41% | +$26.4K | ﹤0.01% | 5306 |
|
|
2019
Q3 | $65K | Sell |
15,566
-10,692
| -41% | -$85.3K | ﹤0.01% | 5771 |
|
|
2019
Q2 | $344K | Buy |
26,258
+19,958
| +317% | +$245K | ﹤0.01% | 4661 |
|
|
2019
Q1 | $60K | Buy |
+6,300
| New | +$24.9K | ﹤0.01% | 5744 |
|
Barclays's PHAS Position: Q1 2023 in Review
Barclays sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2023, closing a stake of 197 shares — an estimated $6 sold.
Barclays first reported a position in PHAS in Q1 2019 and held it in 16 quarters. The position peaked at $344K in Q2 2019. 0 funds tracked by Wall St. Rank hold PHAS as of Q1 2023.
- Barclays reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Barclays sold 197 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $6.
- Barclays first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 16 quarters.
- Barclays's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $344K in Q2 2019.
- 0 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2023.
Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.